



Fig. 1A

Fig. 1B

Fig. 1C

SSEA4 immunostaining





Fig. 2A Fig. 2D Fig. 2G Fig. 2J

Fig. 2B Fig. 2E Fig. 2H Fig. 2K

Fig. 2C Fig. 2F Fig. 2I Fig. 2L

OCT4 immunostaining




Fig. 3A







Fig. 3D


Fig. 3B


Fig. 3E


Fig. 3C




Fig. 3F





Fig. 3J




Fig. 3G


Fig. 3H


Fig. 3K


Fig. 3I



Fig. 3L

DAPI

CY5

Merge

Nanog immunostaining



TRA1-60 Immunostaining






Fig. 5A Fig. 5D Fig. 5G Fig. 5J

Fig. 5B Fig. 5E Fig. 5H Fig. 5K

Fig. 5C Fig. 5F Fig. 5I Fig. 5L

TRA1-81 Immunostaining








Fig. 7A Fig. 7B Fig. 7C Fig. 7D

SSEA4 Immunostaining (after at least 40 passages)



Nanog Immunostaining (after at least 40 passages)





Fig. 9A Fig. 9B Fig. 9C

Fig. 9D Fig. 9E Fig. 9F

Fig. 9G Fig. 9H Fig. 9I

TRA-1-60 immunostaining (at least 40 passages)






Fig. 10A Fig. 10B Fig. 10C

Fig. 10D Fig.10E Fig. 10F

Fig. 10G Fig. 10H Fig. 10I

TRA-1-81 immunostaining (at least 40 passages)



OCT4 immunostaining (at least 40 passages)





Fig. 12A Fig. 12B Fig. 12C

Fig. 12D Fig. 12E Fig. 12F

Fig. 12G Fig. 12H Fig. 12I



Growth Rate – Long Term
Total number of cell
90000000
80000000
70000000
60000000
50000000
40000000
30000000
20000000
10000000
0
0
50
100
150
200
250
300
350
Time (hr)
Wnt
Chir
YFL3

Fig. 13A



Growth Rate (short term, p20)
total number of cells before count
120000000
100000000
80000000
60000000
40000000
20000000
0
0
50
100
150
200
250
300
350
400
YFL3
PMSF
PMSF+Wnt
PMSF+Wnt w.o LIF
PMSF+Chir
PMSF+Chir w.o LIF
PMSF w.o. LIF

Fig. 13B



Growth Rate – Long Term (44-48 passages)
Total number of cells before count
350000000
300000000
250000000
200000000
150000000
100000000
50000000
0
168
192
216
240
264
288
312
336
360
384
408
432
456
480
PMSF+Vitn
YFL3
PMSF
PMSF+Vitn w.o LIF
PMSF+Chir
PMSF+Chir w.o LIF
PMSF w.o. LIF

Fig. 13C



Cycle threshold in RT–PCR
CHIR
Wnt3a
YFL3
More cycles = less mRNA
2-Fold
Medain normalized ct
5
4
3
2
1
NANOG
POU5F1
SOX2
Gene name

Fig. 14

SSEA4 FACS analysis





Fig. 15C





Fig. 15B





Fig. 15A





Fig. 15E





Fig. 15D





Fig. 15G







Fig. 15F




Figs. 16A-L


PMSF + Wnt
267(53)
PMSF + Wnt
w.o. Lif
268(50)
PMSF + Chir
267(49)
A
B
C
D
E
F
G
H
I
J
K
L

Figs. 17A-L





Fig. 18A Fig. 18B Fig. C Fig. 18D Fig. 18E







Fig. 18F Fig. 18G


Fig. 19B
Fig. 19D
DAPI
Ab
Fig. 19A
Oct 4
Fig. 19C
SSEA4


Fig. 20B
Fig. 20D
DAPI
Ab
Fig. 20A
TRA-1-60
Fig. 20C
TRA-1-81

HFF



Fig. 21A

Matrigel




Fig. 21C

MEF




Fig. 21B





Fig. 22





Fig. 23A





Fig. 23B





Fig. 24A





Fig. 24B



Indicated antibody
Isotype control
95.1
0.53
3.55
0.84
0.035
2.34
1.84
95.8
SSEA4
Oct4

Fig. 25



Indicated antibody
Isotype control
Q1
11.2
Q2
86.8
Q3
0.90
Q4
1.11
Q1
1.99
Q2
0.22
Q3
2.06
Q4
95.7
SSEA4
Oct4

Fig. 26





Fig. 27A

Fig. 27B





Fig. 27C